The therapy of chronic myeloid leukemia
10.3760/cma.j.issn.1008-6706.2016.06.042
- VernacularTitle:慢性粒细胞白血病的治疗进展
- Author:
Shanshan WEI
;
Xin TIAN
;
Tilong HUANG
;
Yuehuang YANG
- Publication Type:Journal Article
- Keywords:
Chronic myeloid leukemia;
BCR-ABL fusion gene;
Tyrosine kinase inhibitor;
Hemato-poietic stem cell transplantation
- From:
Chinese Journal of Primary Medicine and Pharmacy
2016;23(6):944-947
- CountryChina
- Language:Chinese
-
Abstract:
The chronic myeloid leukemia( CML) is characterized by a cytogenetic abnormality.The BCR-ABL fusion gene encodes protein 210.With the rapid development of molecular biology and other technologies, the treatment of CML has made great progress.However,patients for TKI resistance,which cannot be tolerated,and TKI will not eliminate CML stem cells.Despite hematopoietic stem cell transplantation( HSCT) is recommended as first-line treatment,it is still faced with many problems.Therefore,to clear CML tiny residual lesions from Ph+malignantly clonal stem cells has become an urgent need,which is expected to be an effective method for CML patients to obtain permanent cure and long-term disease-free survival.In this paper,we review the main advances achieved in the treatment of CML.
